Daiichi Sankyo Announces Reorganization of its Research & Development Structure

For Immediate Release

2015.12.01

Daiichi Sankyo Announces Reorganization of its Research & Development Structure

Tokyo, Japan (December 1, 2015) - Daiichi Sankyo Company, Limited (Chuo-Ku, Tokyo; hereinafter, Daiichi Sankyo) today announced its decision to close its research subsidiary, U3 Pharma GmbH (Martinsried, Germany; hereinafter, U3).

Daiichi Sankyo intends to strengthen its global research and development capabilities by increasing efficiency and streamlining processes. Based on this objective, the global R&D capacities have been reviewed and the Company has decided to concentrate core research functions of Daiichi Sankyo Group in future.

U3, with about 40 employees and which is engaged in research and development work on antibody targeting for cancer treatments, will transfer its current research and development tasks to the Biologics Function in Tokyo.

Daiichi Sankyo will provide a more detailed update on the impact of this announcement on its FY2015 business results at a later date.

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

Suggested Articles

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.

Bluebird has priced gene therapy Zynteglo at €1.575 million in Europe and promised a U.S. price in “reasonably close” range.

Generic pain drug maker Lannett is closing its plant in Wyoming and laying off the remaining 80 employees.